EZH2-IN-13

• CAT Number: I042918
• CAS Number: 1403255-41-3
• Molecular Formula: C34H45N5O3
• Molecular Weight: 571.75
• Purity: ≥95%
• Synonyms: N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(piperazin-1-ylmethyl)phenyl]benzamide
• InChI: InChI=1S/C34H45N5O3/c1-5-39(29-10-16-42-17-11-29)32-20-28(27-8-6-26(7-9-27)22-38-14-12-35-13-15-38)19-30(25(32)4)33(40)36-21-31-23(2)18-24(3)37-34(31)41/h6-9,18-20,29,35H,5,10-17,21-22H2,1-4H3,(H,36,40)(H,37,41)
• InChIKey: CXATYQKHRGXYDA-UHFFFAOYSA-N
• SMILES: CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCNCC5

EZH2-IN-13（Cat No.:I042918）is a small molecule inhibitor designed to target and inhibit EZH2 (Enhancer of Zeste Homolog 2), a protein involved in the regulation of gene expression through histone methylation. EZH2 plays a critical role in cell development and is often overexpressed in various cancers, including lymphomas, prostate cancer, and breast cancer. By inhibiting EZH2, EZH2-IN-13 aims to disrupt tumor cell proliferation and survival. It is being studied for its potential therapeutic applications in oncology, especially for cancers driven by aberrant EZH2 activity, with ongoing clinical research to evaluate its safety and efficacy.